Xinhua news agency, Geneva, June 1 (reporter Liu Qu) - the World Health Organization announced on the 1st that the new crown inactivated vaccine "Kelaifu" developed by China Beijing Kexing Zhongwei Biological Technology Co., Ltd. has officially passed the WHO emergency use certification.

Who director general Tan Desai announced at a press conference on the same day that the koshing new crown vaccine has been proved to be "safe, effective and quality guaranteed" and has been included in the WHO emergency use list. In addition, the easy storage of the vaccine makes it very suitable for resource deficient environments.

According to the advice of the WHO advisory expert group on immunization strategy, who recommends that koshing vaccine be used for adults aged 18 and over, with two doses at an interval of 2 to 4 weeks. The data showed that the effective rate of the vaccine in preventing new crown symptoms was 51%, and the effective rate in preventing severe new crown and hospitalization was 100%.

Although there are few data on people over the age of 60 participating in the clinical trial of Kexing vaccine, who does not recommend setting an upper age limit for the use of the vaccine, because a variety of data show that the vaccine may also have a protective effect on the elderly.

Marian gerra simang, who assistant director general for access to drugs and health products, said in a statement that the world urgently needs a variety of new vaccines to solve the huge global inequality in vaccine access. Who urged vaccine manufacturers novel coronavirus pneumonia to participate in the new "cap vaccine implementation plan", sharing their expertise and data to contribute to the control of the new crown pandemic.

Kexing vaccine is the second Chinese new crown vaccine that has been included in the WHO emergency use list after the Chinese new crown vaccine. In addition to the two Chinese vaccines, who has previously issued emergency use certification to a number of new crown vaccines, including the new crown vaccine jointly developed by Pfizer Pharmaceutical Co., Ltd. of the United States and new biotechnology company of Germany, and the two versions of AstraZeneca vaccine jointly developed by AstraZeneca Pharmaceutical Co., Ltd. of the United Kingdom and Oxford University, The new crown vaccine developed by Johnson & Johnson's Janssen Pharmaceutical Company and the new crown vaccine developed by Modena company.